Nuvation Bio announced $18.5 million in net product revenue for IBTROZI (taletrectinib) in Q1 2026, with strong adoption among newly treated patients with advanced ROS1-positive NSCLC. The company also acquired global development and commercialization rights to safusidenib, an investigational drug for IDH1-mutant glioma, expanding its oncology portfolio. Updated clinical data showed IBTROZI's durable response and progression-free survival, supporting its growing role as a standard treatment. Nuvation Bio maintains a strong cash position of $533.7 million and plans further updates on its drug conjugate platform later in 2026.
Dycom Industries reported a record first quarter with contract revenues up 56.1% to $1.965 billion and adjusted net income nearly doubling to $134.3 million. The company raised its full-year fiscal 2027 revenue outlook to $7.38-$7.65 billion, driven ...
BrewDog, part of Tilray Brands, is rolling out a major summer campaign across the UK tied to the global football tournament. The campaign features a "Win a Year of Beer" contest with special cans hidden in over 2.8 million packs at major retailers, p...
Autolus Therapeutics, a biopharmaceutical company specializing in next-generation T cell therapies, announced it will present at two upcoming investor conferences: William Blair’s Growth Stock Conference on June 2 and Jefferies Global Healthcare Conf...
Infrastructure Capital Advisors announced the first monthly dividend of $1 per share for its Infrastructure Capital Nasdaq Option Income ETF (QVOL), targeting an annualized distribution rate of 12-15%. The firm also declared monthly dividends for its...
G-III Apparel Group announced a quarterly cash dividend of $0.10 per share, payable on July 8, 2026, to shareholders of record as of June 22, 2026. This dividend reflects the company's ongoing commitment to returning value to its investors. G-III is ...
